Payment overview · 2025
General Payments
$1,805.86
96 reported records · 22 companies
Healthcare provider profile · identity verified
Pedro Daniel Gonzalez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AZLE, TX · NPI 1609846682
Verified facts
What the public records show
CMS Open Payments records show Pedro Daniel Gonzalez, M.D. received $1,805.86 in general payments during 2025 across 96 reported records.
Inspire Medical Systems, Inc. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $350.07 | 19.4% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $269.44 | 14.9% | 19 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $166.74 | 9.2% | 14 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $152.88 | 8.5% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $147.50 | 8.2% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $106.95 | 5.9% | 5 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $105.18 | 5.8% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.90 | 3.4% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $61.44 | 3.4% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $57.11 | 3.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.73 | 2.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.72 | 2.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.08 | 2.4% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $34.49 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.05 | 1.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.94 | 1.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.95 | 1.0% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $17.48 | 1.0% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $15.42 | 0.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.21 | 0.8% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $14.35 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.23 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,805.86 | 96 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $350.07 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $269.44 | 19 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $152.88 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $147.50 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $131.14 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $129.05 | 7 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $105.18 | 6 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $68.99 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $61.44 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $57.11 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $48.73 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $46.72 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.13 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $37.96 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.60 | 7 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $34.49 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.94 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.94 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| Secuado Normalized: secuado |
Drug | Noven Therapeutics, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 159 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 109 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
93 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 43 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 586 | 215 |
| Atorvastatin Calcium | Atorvastatin Calcium | 565 | 216 |
| Amlodipine Besylate | Amlodipine Besylate | 535 | 189 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 445 | 167 |
| Lisinopril | Lisinopril | 345 | 143 |
| Montelukast Sodium | Montelukast Sodium | 339 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 292 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 290 | 108 |
| Gabapentin | Gabapentin | 287 | 107 |
| Alprazolam | Alprazolam | 279 | 55 |
| Omeprazole | Omeprazole | 259 | 92 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 253 | 79 |
| Furosemide | Furosemide | 246 | 90 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 245 | 43 |
| Allopurinol | Allopurinol | 238 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 197 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 71 |
| Metformin Hcl | Metformin Hcl | 181 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 178 | 57 |
| Losartan Potassium | Losartan Potassium | 178 | 75 |
| Lorazepam | Lorazepam | 166 | 38 |
| Potassium Chloride | Potassium Chloride | 166 | 63 |
| Metformin Hcl Er | Metformin Hcl | 162 | 55 |
| Eliquis | Apixaban | 159 | 43 |
| Ozempic | Semaglutide | 158 | 40 |
| Tramadol Hcl | Tramadol Hcl | 157 | 46 |
| Clonazepam | Clonazepam | 149 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 57 |
| Simvastatin | Simvastatin | 137 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 136 | 39 |
| Ezetimibe | Ezetimibe | 133 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 51 |
| Meloxicam | Meloxicam | 125 | 50 |
| Memantine Hcl | Memantine Hcl | 125 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 60 |
| Sertraline Hcl | Sertraline Hcl | 116 | 43 |
| Carvedilol | Carvedilol | 113 | 42 |
| Bupropion Xl | Bupropion Hcl | 111 | 33 |
| Buspirone Hcl | Buspirone Hcl | 110 | 37 |
| Jardiance | Empagliflozin | 109 | 35 |
| Glimepiride | Glimepiride | 96 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 39 |
| Trazodone Hcl | Trazodone Hcl | 94 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 29 |
| Celecoxib | Celecoxib | 89 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 31 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 79 | 11 |
| Mounjaro | Tirzepatide | 67 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 24 |
| Eszopiclone | Eszopiclone | 63 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 16 |
| Prednisone | Prednisone | 60 | 45 |
| Atenolol | Atenolol | 59 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 21 |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Myrbetriq | Mirabegron | 52 | 14 |
| Carisoprodol | Carisoprodol | 51 | suppressed |
| Estradiol | Estradiol | 51 | 22 |
| Rybelsus | Semaglutide | 49 | 17 |
| Spironolactone | Spironolactone | 49 | 15 |
| Nitroglycerin | Nitroglycerin | 47 | 24 |
| Fenofibrate | Fenofibrate | 46 | 16 |
| Ondansetron Odt | Ondansetron | 46 | 12 |
| Benazepril Hcl | Benazepril Hcl | 45 | 15 |
| Warfarin Sodium | Warfarin Sodium | 45 | 14 |
| Temazepam | Temazepam | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 17 |
| Alendronate Sodium | Alendronate Sodium | 40 | 14 |
| Clonidine Hcl | Clonidine Hcl | 39 | 18 |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Buprenorphine | Buprenorphine | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 15 |
| Methocarbamol | Methocarbamol | 37 | 18 |
| Xarelto | Rivaroxaban | 37 | 15 |
| Finasteride | Finasteride | 36 | 14 |
| Glipizide | Glipizide | 36 | 17 |
| Lovastatin | Lovastatin | 36 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 12 |
| Diazepam | Diazepam | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | 15 |
| Pregabalin | Pregabalin | 32 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 14 |
| Valsartan | Valsartan | 31 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 25 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | 11 |
| Testosterone | Testosterone | 27 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | 11 |
| Promethazine Hcl | Promethazine Hcl | 25 | 17 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Methadone Hcl | Methadone Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Belbuca | Buprenorphine Hcl | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Dupixent Syringe | Dupilumab | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Nystatin | Nystatin | 17 | 11 |
| Ramipril | Ramipril | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 14 |
| Linzess | Linaclotide | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Febuxostat | Febuxostat | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Baclofen | Baclofen | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Tymlos | Abaloparatide | 12 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Butrans | Buprenorphine | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,805.86 · 96 records | Inspire Medical Systems, Inc. | AREXVY, Auvelity, Azstarys, CAPLYTA, CYCLOSET, Cologuard Collection Kit, Dexcom G6 Transmitter, Doc Band, ELIQUIS, FREESTYLE LIBRE, Heplisav-B, INSPIRE, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, SHINGRIX, Secuado, Symbravo, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, VRAYLAR, XYOSTED, Xelstrym, YUPELRI, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error